• Thyroid hormone receptor agonist improves liver fat, lipoproteins in NASH

    10 monthes ago - By Healio

    Madrigal Pharmaceuticals announced positive interim results from a phase 2 clinical trial of MGL-3196 for reducing liver fat in patients with nonalcoholic steatohepatitis, according to a press release and company presentation.
    Paul A. Friedman Rebecca Taub
    “The drug has the potential as monotherapy once a day to treat this disease state and the drug could also be combined with any number of other drugs in development that have different mechanisms,” Paul A. Friedman, MD, chairman and CEO of Madrigal Pharmaceuticals, told Healio Gastroenterology and Liver Disease.
    MGL-3196 is an oral,
    Read more ...